Canada - English - Health Canada

pharmascience inc - trandolapril - capsule - 0.5mg - trandolapril 0.5mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

pharmascience inc - trandolapril - capsule - 1mg - trandolapril 1mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

pharmascience inc - trandolapril - capsule - 2mg - trandolapril 2mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

pharmascience inc - trandolapril - capsule - 4mg - trandolapril 4mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

teva canada limited - trandolapril - capsule - 0.5mg - trandolapril 0.5mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

teva canada limited - trandolapril - capsule - 1mg - trandolapril 1mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

teva canada limited - trandolapril - capsule - 2mg - trandolapril 2mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

teva canada limited - trandolapril - capsule - 4mg - trandolapril 4mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

laboratoire riva inc. - trandolapril - capsule - 2mg - trandolapril 2mg - angiotensin-converting enzyme inhibitors

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - trandolapril (unii: 1t0n3g9crc) (trandolaprilat - unii:rr6866vl0o) - hypertension trandolapril tablets usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. heart failure post myocardial infarction or left-ventricular dysfunction post myocardial infarction trandolapril tablets usp are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of trandolapril to caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see clinical pharmacology -heart failure or left-ventricular dysfunction post myocardial infarction for details of the survival trial). trandolapril tablets are contraindicated in patients who are hypersensitive to this product, in patients wi